The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Fate Therapeutics Inc shares valued at $668,580 were purchased by Redmile Group, LLC on Dec 20 ’24. At $1.68 per share, Redmile Group, LLC acquired 397,964 shares. The insider’s holdings grew to 12,884,277 shares worth approximately $20.87 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Redmile Group, LLC sold 341,633 shares, netting a total of over 573,943 in proceeds. Following the sale of shares at $1.68 each, the insider now holds 12,486,313 shares.
Before that, Redmile Group, LLC had added 341,633 shares to its account. In a trade valued at $567,111, the Director, 10% Stockholder bought Fate Therapeutics Inc shares for $1.66 each.
As published in a research note from BofA Securities on November 18, 2024, Fate Therapeutics Inc [FATE] has been rated up from an Underperform to a Neutral. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in mid June. Earlier on January 24, 2023, H.C. Wainwright downgraded its rating. Their new recommendation was “a Neutral” for FATE stock which previously was a “a Buy”.
Analyzing FATE Stock Performance
During the last five days, there has been a drop of approximately -3.86%. Over the course of the year, Fate Therapeutics Inc shares have dropped approximately -56.68%. Shares of the company reached a 52-week high of $8.8300 on 03/07/24 and a 52-week low of $1.5600 on 12/26/24. A 50-day SMA is recorded $2.4441, while a 200-day SMA reached $3.8373. Nevertheless, trading volume fell to 2.17 million shares from 1.03 million shares the previous day.
Support And Resistance Levels for Fate Therapeutics Inc (FATE)
According to the 24-hour chart, there is a support level at 1.5700, which, if violated, would cause prices to drop to 1.5200. In the upper region, resistance lies at 1.6600. The next price resistance is at 1.7000. RSI (Relative Strength Index) is 34.52 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.3123, which suggests the price will decrease in the coming days. Percent R is at 95.62%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
